Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Chebli Mrad"'
Autor:
Abhay Singh, Megan M. Herr, Elizabeth A. Griffiths, Amanda Przespolewski, Mark G. Faber, Chebli Mrad, Eunice S. Wang, Theresa Hahn, Swapna Thota
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Clonal hematopoiesis (CH) is a risk factor for the development of therapy-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML). Adoption of targeted-immunotherapeutics since 2011, may alter the risk of CH progression to
Externí odkaz:
https://doaj.org/article/ad170899005a44ae897c0ca8999eacac
Autor:
Amanda Przespolewski, Megan M. Herr, Elizabeth A. Griffiths, Mark G. Faber, Eunice S. Wang, Swapna Thota, Abhay Singh, Theresa Hahn, Chebli Mrad
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports
Clonal hematopoiesis (CH) is a risk factor for the development of therapy-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML). Adoption of targeted-immunotherapeutics since 2011, may alter the risk of CH progression to tMDS/AML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b3b4550d5d4945a938e01f5cbb767d
https://doaj.org/article/ad170899005a44ae897c0ca8999eacac
https://doaj.org/article/ad170899005a44ae897c0ca8999eacac
Autor:
Marita Yaghi, Nadeem Bilani, Barbara Dominguez, Iktej Singh Jabbal, Carlos Rivera, Hong Liang, Paul X Benedetto, Chebli Mrad, Zeina A. Nahleh, Rafael Arteta-Bulos
Publikováno v:
Journal of Clinical Oncology. 40:e21585-e21585
e21585 Background: Sentinel lymph node biopsy (SLNB) remains controversial in patients with localized marginal thickness melanoma (MTM). Nonetheless, micrometastasis (miLN) i.e. the presence of clinically occult lymph node (LN) metastasis, upstages l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64d07dae12abd0a13d55b8944b0ad376
https://doi.org/10.1200/jco.2022.40.16_suppl.e21585
https://doi.org/10.1200/jco.2022.40.16_suppl.e21585
Publikováno v:
Journal of Oncology Practice. 14:e746-e757
Background: Patients with metastatic lung cancer are treated with palliative intent. Aggressive care at the end of life is a marker of poor-quality care. National trends and factors related to aggressive inpatient care at the end of life for these pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03be28f703eaea610613d902273bdfd0
https://doi.org/10.1200/jop.18.00515
https://doi.org/10.1200/jop.18.00515
Autor:
Mizuki Nishino, Andrew J. Plodkowski, Joseph Montecalvo, Chebli Mrad, Charles M. Rudin, Lynette M. Sholl, Wei-Chu Victoria Lai, Mark G. Kris, Giulia Costanza Leonardi, Ai Ni, Renato Umeton, Mark M. Awad, Joshua K. Sabari, N. Rekhtman, Michael Offin, A. Drilon, Bob T. Li, Ruqin Chen, Darragh Halpenny, Catherine A. Shu, Kathryn C. Arbour, Matthew D. Hellmann, G. J. Riely, Isabella Bergagnini, Jules L. Dienstag, Paul K. Paik
Publikováno v:
Annals of Oncology. 29:2085-2091
BACKGROUND: MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung cancers in prospective trials. In contrast, the activity of immunotherapy, PD-L1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e209ed6c64fb3bcd54692dba49c5f2e7
https://doi.org/10.1093/annonc/mdy334
https://doi.org/10.1093/annonc/mdy334
Autor:
Joshua K. Sabari, Chebli Mrad, Alexander Drilon, W. Victoria Lai, Isabella Bergagnini, Ruqin Chen, Alison M. Schram, Kathryn C. Arbour, Fernando C. Santini
Publikováno v:
OncoTargets and Therapy. 10:1983-1992
Brigatinib (AP26113) is a dimethylphosphine oxide group-containing tyrosine kinase inhibitor (TKI) constructed around a bisanilinopyrimidine scaffold with potent activity against the anaplastic lymphoma kinase (ALK) and several other targets. Despite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::004fafeb462a4c8fc8b951659b7b5fc8
https://doi.org/10.2147/ott.s109295
https://doi.org/10.2147/ott.s109295
Publikováno v:
American Journal of Gastroenterology. 112:S299-S301
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2062b3aaafa8fe90a853a4bc554714c3
https://doi.org/10.14309/00000434-201710001-00559
https://doi.org/10.14309/00000434-201710001-00559
Autor:
Megan M. Herr, Mark G. Faber, Abhay Singh, Eunice S. Wang, Swapna Thota, Chebli Mrad, Theresa Hahn
Publikováno v:
Journal of Clinical Oncology. 38:7516-7516
7516 Background: Data describing risks of tMDS/AML after targeted and immunotherapy (IO) agents are lacking. Melanoma (Mel) and renal cell carcinoma (RCC) are considered chemotherapy insensitive and have been treated with IO (interferon and interleuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a52112ee7127897dea7a29ffb40dcebd
https://doi.org/10.1200/jco.2020.38.15_suppl.7516
https://doi.org/10.1200/jco.2020.38.15_suppl.7516
Publikováno v:
Journal of clinical gastroenterology. 53(2)
GOALS To quantify in patients with nonvariceal upper gastrointestinal hemorrhage (NVUGIH) the relationship between obesity and mortality, disease severity, treatment modalities, and resource utilization. BACKGROUND NVUGIH is the most common gastroint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8f5f02b5f5c01b249c76c129d5d7a13
https://pubmed.ncbi.nlm.nih.gov/29035976
https://pubmed.ncbi.nlm.nih.gov/29035976
Publikováno v:
Journal of Clinical Oncology. 36:26-26
26 Background: Metastatic lung cancer patients are treated with palliative intent. Aggressive inpatient care at the end-of-life is seen as a marker of poor quality care. However, national trends and factors related to aggressive inpatient care at the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a48d0593ad5df2bb36ec1ef5e0af4a8a
https://doi.org/10.1200/jco.2018.36.30_suppl.26
https://doi.org/10.1200/jco.2018.36.30_suppl.26